Myelomide (Lenalidomide)

Lenalidomide, the active ingredient in Myelomide, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes, in adult patients.

GNH USA supplies Myelomide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Myelomide, an immunomodulatory agent, is employed in the management of specific hematologic malignancies.

Multiple myeloma: improves disease control and prolongs progression‑free survival in relapsed or refractory patients. Mantle cell lymphoma: contributes to response rates when used in combination regimens. Myelodysplastic syndromes: reduces transfusion dependence and delays transformation to acute leukemia.

Adverse reactions may occur with lenalidomide therapy and are categorized by frequency and severity.

Common Side Effects: - Fatigue - Nausea - Diarrhea - Neutropenia - Rash - Constipation

Serious or Rare Side Effects: - Thromboembolic events - Severe neutropenia or leukopenia - Secondary primary malignancies - Hepatic dysfunction - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Embryo‑fetal toxicity (Category X).

Lenalidomide requires careful monitoring and patient counseling due to its risk profile.

Pregnancy: contraindicated; strict contraception required (Category X). Thrombosis risk: assess history and consider prophylaxis. Renal impairment: monitor renal function and adjust therapy as needed. Hematologic monitoring: perform regular complete blood counts. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lenalidomide may interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lenalidomide exposure. - Anticoagulants: heightened risk of bleeding. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce therapeutic levels. - Nephrotoxic agents: monitor renal function closely. - Immunosuppressants: watch for additive immunosuppression.